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Abstract: In this study, hydrogel scaffolds, based on the
polymer oligo(poly(ethylene glycol) fumarate) (OPF), were
implanted into osteochondral defects in the rabbit model.
Scaffolds consisted of two layers—a bottom, bone forming
layer and a top, cartilage forming layer. Three scaffold for-
mulations were implanted to assess how material composi-
tion and transforming growth factor-1 (TGF-1) loading
affected osteochondral repair. Critical histological evalua-
tion and scoring of the quantity and quality of tissue in the
chondral and subchondral regions of defects was performed
at 4 and 14 weeks. At both time points, no evidence of
prolonged inﬂammation was observed, and healthy tissue
was seen to inﬁltrate the defect area. The quality of this
tissue improved over time with hyaline cartilage ﬁlling the
chondral region and a mixture of trabecular and compact
bone ﬁlling the subchondral region at 14 weeks. A promis-
ing degree of Safranin O staining and chondrocyte organi-
zation was observed in the newly formed surface tissue,
while the underlying subchondral bone was completely in-
tegrated with the surrounding bone at 14 weeks. Material
composition within the bottom, bone-forming layer did not
appear to affect the rate of scaffold degradation or tissue
ﬁlling. However, no bone upgrowth into the chondral region
was observed with any scaffold formulation. TGF-1 load-
ing in the top layer of scaffolds appeared to exert some
therapeutic affect on tissue quality, but further studies are
necessary for scaffold optimization. Yet, the excellent tissue
ﬁlling and integration resulting from osteochondral implan-
tation of these OPF-based scaffolds demonstrates their po-
tential in cartilage repair strategies. © 2005 Wiley Periodi-
cals, Inc. J Biomed Mater Res 75A: 156–167, 2005
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INTRODUCTION
Chronic joint pain and arthritis affects approxi-
mately one-third of adults in the United States,1 and is
the leading causes of disabilities among Americans.2
Many of these individuals suffer from lesions to artic-
ular cartilage, the thin tissue lining diarthrodial joints
that dissipates compressive loads and allows for pain-
free movement.3 Lesions, commonly inﬂicted during
improper joint loading, sudden joint rotation, or direct
impact to a joint, often fail to heal properly due to the
complex structure of this unique tissue.3,4 In particular,
articular cartilage is an avascular tissue with a relatively
sparse cell population and a dense, well-ordered extra-
cellular matrix.5,6 Because articular cartilage exhibits lim-
ited intrinsic repair, lesions may lead to further joint
degeneration and the onset of osteoarthritis.4,7,8
Treatment options for patients with articular carti-
lage lesions are currently restricted to surgical proce-
dures aimed at either stimulating a healing response
at the injury site or ﬁlling the lesion with a tissue
graft.7,9 The former strategy is undertaken by invasive
drilling to deepen cartilage lesions to access the bio-
active molecules and reparative cells in the underlying
bone marrow. The strategy of tissue grafting requires
surgical disruption of healthy tissue to harvest a
Correspondence to: J. A. Jansen; e-mail: j.jansen@dent.
umcn.nl
Contract grant sponsor: the National Institutes of Health;
contract grant number: R01 AR48756 (to A.G.M.)
Contact grant sponsor: Whitaker Foundation Graduate
Fellowship (to T.A.H.)
© 2005 Wiley Periodicals, Inc.
source of cartilage, periosteal, or perichondrial cells for
subsequent transplantation at the lesion site. Thus, both
treatment options inﬂict further tissue destruction before
any therapeutic effect can be achieved. Additionally,
both surgical strategies have demonstrated very limited
long-term efﬁcacy. In general, surgical abrasion or dril-
ling appears to produce mainly ﬁbrocartilage or ﬁbrous
tissue at the repair site, which often deteriorates over
time.5,9,10 Graft delamination and endochondral ossiﬁca-
tion are frequently encountered following tissue trans-
plantation.9–11 Accordingly, new treatment options are
necessary for the treatment of articular cartilage defects.
Through a series of investigations, our laboratory
has developed a novel class of injectable materials for
the delivery of bioactive molecules to cartilage lesions
to enhance tissue repair.12–14 These systems are based
on oligo(poly(ethylene glycol) fumarate) (OPF), a syn-
thetic polymer that can be used to fabricate biodegrad-
able and biocompatible hydrogels.15,16 OPF, a water
soluble polymer, can be injected into a defect site and
crosslinked in situ at physiological conditions, thereby
eliminating the need for harsh surgeries. Gelatin mi-
croparticles, incorporated into these gels at the time of
crosslinking, have been shown to act as enzymatically,
digestible porogens to speed scaffold degradation.14
Sustained growth factor delivery has been achieved by
ﬁrst loading these microparticles with the desired
growth factor and then encapsulating the micropar-
ticles within the OPF network.12–14
This current work evaluates three different formu-
lations of bilayered OPF hydrogel scaffolds in osteo-
chondral repair. A bilayered scaffold design (Table I)
was employed to spatially control drug loading and
scaffold degradability in the approximate regions
where cartilage and bone are found in healthy joints.
For all formulations, the upper scaffold layer consisted
of an OPF hydrogel in which 0.20 g gelatin micropar-
ticles per gram polymer were encapsulated. This scaf-
fold composition was utilized because microparticles
embedded in the OPF network at this concentration
have previously been shown to act as digestible poro-
gens.14 Accordingly, it was hypothesized that this
composition would allow for rapid and adequate cell
inﬁltration to the chondral portion of defects from the
surrounding cartilage and synovium.17
In two scaffold formulations (abbreviated as C /C
and C /H), microparticles within this upper compos-
ite layer were loaded with transforming growth fac-
tor-1 (TGF-1), while microparticles in the third scaf-
fold formulation (abbreviated as C/H) were loaded
with PBS. TGF-1 is an excellent candidate for carti-
lage drug delivery strategies as this growth factor has
been shown to enhance chondrocyte proliferation18,19
to promote the chondrogenic differentiation of pro-
genitor cells,20–22 and to increase cartilage extracellu-
lar matrix synthesis.23–25 The bottom layer of all scaf-
folds was unloaded (TGF-1-free) because TGF-1
delivery to the osseous tissue of osteochondral defects
has resulted in bone upgrowth into the cartilaginous
region of defects.26 In two scaffold formulations (C
/H and C/H), the bottom layer was composed solely
of an OPF hydrogel without any porogen. This mate-
rial composition was chosen to act as a structural
barrier to further prevent bone upgrowth, because
OPF hydrogels have been shown to degrade slower
than OPF–gelatin microparticle composite gels.14
Histological evaluation of the quantity and quality
of tissue repair in the upper and lower portion of
defects treated with these three scaffold formulations
was performed at both 4 and 14 weeks to assess the
following questions:
1. Do these novel, hydrogel scaffolds support carti-
lage and bone growth in the rabbit osteochondral
defect model?
2. How does the quality and quantity of tissue re-
pair compare over time?
3. Does the rate of material degradation in the
lower, bone forming portion of scaffolds affect
tissue formation?
4. How does TGF-1 delivery to the upper portion
of osteochondral defects affect cartilage repair?
EXPERIMENTAL METHODS
Gelatin microparticle fabrication and loading
Gelatin microparticles were fabricated from acidic gel-
atin (Nitta Gelatin Inc., Osaka, Japan) and crosslinked in
TABLE I
Material Composition and TGF-1 Loading in the Upper and Lower Layers of the Three Formulations of OPF
Scaffolds Implanted into Osteochondral Defects
Scaffold Formulations
C/C C/H C/H
Chondral layer Composite: Gel encapsulating
TGF-1-loaded
microparticles
Composite: Gel encapsulating
TGF-1-loaded
microparticles
Composite: Gel encapsulating
blank microparticles
Subchondral layer Composite: Gel encapsulating
blank microparticles
Hydrogel with no
microparticles or TGF-1
Hydrogel with no
microparticles or TGF-1
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10 mM glutaraldehyde (Sigma, St. Louis, MO) according
to previously established methods.27 After drying, the
microparticles were sieved to obtain particles 50–100 m
in size and then sterilized by exposure to ethylene oxide
gas.28
Sterile microparticles were then loaded with TGF-1 by
swelling in an aqueous solution of TGF-1 at pH 7.4 accord-
ing to previous methods.13,14 At this pH, TGF-1 (with an
isoelectric point of 9.5) is positively charged, and therefore,
forms a polyionic complexation with negatively charged
acidic gelatin (isoelectric point of 5.0).27,28 A TGF-1 loading
solution concentration of 1.2 g TGF-1/mL PBS was uti-
lized to achieve an overall growth factor loading of approx-
imately 200 ng TGF-1/mL in the top crosslinked, layer of
scaffolds. This concentration of TGF-1 has previously been
shown to be therapeutic in the treatment of full and partial
thickness rabbit and porcine defects.26,29 Blank micropar-
ticles were loaded with PBS in a similar fashion.
OPF synthesis
OPF with an initial number average molecular weight of
12,300  100 and weight average molecular weight of
51,300  6,700 was synthesized according to a method de-
veloped in our laboratory.30 Molecular weight determina-
tion was likewise conducted using established procedures
for gel permeation chromatography with samples run in
triplicate.14 The resulting OPF was sterilized by exposure to
UV light for 3 h following an established technique.31
Scaffold fabrication
Table I displays the three different scaffold formulations
fabricated for this study. All scaffolds consisted of two lay-
ers: a top cartilage-forming layer, and a bottom bone-form-
ing layer with respective thicknesses of 1 and 2 mm. Al-
though the thickness of articular cartilage was expected to
vary among animals, these dimensions were chosen as a
means of tailoring scaffold composition and drug loading to
the upper or lower portion of defects, rather than as a model
of exact anatomy. Because the animals utilized in this study
were already undergoing bilateral joint surgery for creation
of the osteochondral defects, scaffolds were implanted,
rather than injected, at the defect site.
As noted in Table I, the scaffold formulations have been
assigned abbreviations based on the material compositions
within each layer—either an OPF hydrogel layer (H) or a
composite gel layer (C) in which gelatin microparticles were
encapsulated in the OPF network. The ﬁrst letter of each
abbreviation corresponds to the material composition of the
upper, cartilage-forming layer. Subscripts “” or “ ” re-
spectively refer to upper layers containing microparticles
loaded with PBS or loaded with TGF-1. No growth factors
were added to the bottom bone-forming layer of any scaf-
fold formulation.
All scaffolds were fabricated using a two-step crosslinking
procedure (Fig. 1) in which an OPF solution with the desired
bottom layer composition was ﬁrst injected into a mold and
partially crosslinked prior to the injection and crosslinking
of the upper layer. More speciﬁcally, 0.15 g OPF was dis-
solved in 395 l of PBS containing 14 mg N,N-methylene
bisacrylamide (Sigma, St. Louis, MO) as a crosslinking
Figure 1. Overview of the methods utilized for scaffold fabrication and implantation, as well as subsequent retrieval and
processing of tissue.
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agent. Then, the appropriate amount of microparticles (32 or
0 mg) was added to the polymer solution with an additional
118 L PBS. The resulting mixture was thoroughly vortexed.
Finally, 51 L of 0.3 M tetramethylethylenediamine (in PBS)
(Sigma, St. Louis, MO) and 51 L of 0.3 M ammonium
persulfate (in PBS; Sigma, St. Louis, MO) were added to
initiate crosslinking. After vortexing, the suspension was
injected into a cylindrical Teﬂon mold (3 mm in diameter) to
a height of 2 mm and incubated at 37°C to achieve crosslink-
ing. The cytocompatibility of this tetramethylethylenedia-
mine/ammonium persulfate initiating system has previ-
ously been demonstrated by the successful encapsulation of
rat marrow stromal cells in OPF hydrogels during the time
of crosslinking.31,32
After 5-min incubation, this formulation of OPF forms a
partially crosslinked hydrogel, enabling lamination to a sec-
ond layer.14,33 Accordingly, at this time, a second solution of
OPF–gelatin microparticles was injected into the Teﬂon
mold to form the upper scaffold layer (1 mm in height). Prior
to injection, this solution was mixed as previously described.
The mold was then incubated at 37°C for 10 min to achieve
complete crosslinking of both layers. It should be noted that
all PBS, initiator, and bisacrylamide solutions were sterilized
prior to use by ﬁltration through a cellulose acetate mem-
brane ﬁlter (0.2 m pore diameter) according to an estab-
lished procedure.31 The ﬁnal dimensions of all scaffolds
matched the dimensions of osteochondral defects in the
rabbit model (3 mm in diameter  3 mm in depth).34–36
Scaffolds were fabricated 2 to 4 h prior to implantation.
Animal surgery
Seventeen, 4-month-old New Zealand white rabbits were
utilized in this study. All surgical procedures followed pro-
tocols approved by the University of Nijmegen’s Animal
Care and Use Committee and were based on a well-estab-
lished bilateral, rabbit, osteochondral defect model.34–36
Eight of the 17 rabbits were used to examine tissue repair at
4 weeks, with the remaining nine rabbits utilized to examine
repair at 14 weeks.
Prior to surgery, anesthesia was induced by an intrave-
nous injection of Hypnorm (0.32 mg/mL fentanyl citrate
and 10 mg/mL ﬂuanisone) and atropine. General inhalation
anesthesia was then maintained by a mixture of nitrous
oxide, isoﬂurane, and oxygen administered through a con-
stant volume ventilator. To reduce peri-operative infection
risk and to minimize postoperative discomfort, antibiotic
prophylaxis (Baytril 2.5%, Enroﬂoxacin, 5–10 mg/kg) and
Fynadyne were preoperatively administered to the rabbits.
After administration of anesthesia, rabbits were immobi-
lized on their back. Hair from both legs of each animal was
shaved, and the legs disinfected with povodine–iodine. Both
knee joints were then exposed through a medial parapatellar
longitudinal incision. The capsule was incised, and the me-
dial femoral condyle exposed after lateral luxation of the
patella. With the knee maximally ﬂexed, a full-thickness
defect (3 mm in diameter and 3 mm in depth) was created in
the center of the condyle using a dental drill (KAVO, Intra-
sept 905, KAVO Nederland BV, Vianen, The Netherlands). A
2-mm drill bit was ﬁrst used to establish a 2-mm diameter
defect. This defect was then irrigated and gradually en-
larged using drill bits with a diameter of 2.8 mm and then
3.0 mm. All bits were fashioned with a 3 mm stop to ensure
a defect of precisely 3 mm in depth was created. All debris
was removed from the defect with a curette and the edge
carefully cleaned with a scalpel blade.
A scaffold was then placed into the defect. Subsequently,
the patella was repositioned, and the capsule and muscle
closed with a continuous 4-0 Vicryl suture. Finally, the skin
was closed with single intracutaneous 4-0 Vicryl sutures.
This procedure was repeated for both knees of each rabbit
with different scaffold formulations implanted into the right
and left knees of each rabbit. More speciﬁcally, ﬁve rabbits
received one C /H scaffold and one C /C scaffold, while
an additional six rabbits received one C/H scaffold and
one C /H scaffold. Finally, the last six rabbits received one
C /C and one C/H scaffold.
To minimize postoperative discomfort, Fynadyne was
administered for 2 days postoperatively. The animals were
housed in conventional rabbit cages that allowed for unre-
stricted weight-bearing activity and were observed for signs
of pain, infection, and proper activity.
Tissue processing
At 4 and 14 weeks postsurgery, rabbits were euthanized
by intravenous administration of Nembutal (pentobarbital).
The tissue surrounding the medial femoral condyle was
retrieved en bloc. Specimens were ﬁxed in 10% buffered
formalin (pH 7.4) for 1 week, decalciﬁed in Formical2000
(Decal Corporation, Congers, NY) for 2 weeks, dehydrated
through graded ethanols, and embedded in parafﬁn. Using
a microtome (Leica RM 2165, Leica Microsystems, Nussloch,
Germany), longitudinal sections of 6 m in thickness were
taken throughout the defect. Sections from the defects’ cen-
ter and lateral and medial edges were then stained with
hematoxylin and eosin (H&E). Likewise, center, lateral, and
medial sections were separately stained with Safranin
O/light green and Masson’s trichrome. This methodical pro-
cessing of the sections allowed for subsequent evaluation of
tissue repair at the defect edges and center.
In addition to standard H&E, the two additional staining
methods enabled identiﬁcation of key attributes of the newly
formed tissue—in particular, glycoasminoglycan and colla-
gen content. Safranin O is routinely used in cartilage histol-
ogy because this stain colors basophilic structures, like the
negatively charged glycoasminoglycans of articular carti-
lage, with shades of red. Light green is a neutral stain
utilized as a counter stain in Safranin O-stained sections.
Masson’s trichrome staining is also a well-established histo-
logical technique for evaluating connective tissue. This tech-
nique identiﬁes collagen ﬁbers with a green color, while cell
nuclei and cytoplasm are respectively stained black and
red.37
Histological scoring
Histological sections were blindly and independently
scored by two evaluators (TH and EB) using a modiﬁed
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graded system based on the ﬁve histological characteristics
examined in the original O’Driscoll method for examining
tissue graft performance: graft integration and integrity, and
cartilage morphology, regularity, and thickness.38 However,
because the present study examined the performance of
degradable implants, rather than tissue grafts, this system
was amended to examine neo-tissue ingrowth and integra-
tion, rather than graft integrity and integration (Table II).
Additionally, because the material composition of the bot-
tom subchondral layer of these implants was varied to ex-
amine how the rate of implant degradation affected tissue
formation, parameters were also included to separately ex-
amine neo-tissue ingrowth and morphology in this region.
Overall implant degradation was also scored.
Finally, following well-established modiﬁcations to the
original O’Driscoll system, additional parameters examined
potential chondrocyte clustering within the newly formed
cartilaginous tissue,39–41 as well as the cellularity and GAG
content (assessed by Safranin O staining) within the neo-
tissue and in the cartilage immediately adjacent to the de-
fect.36,39,41 Similarly, apparent total collagen content in the
neo-tissue was assessed by Masson’s trichrome staining.
These parameters were scored relative to the respective
characteristics of uninjured cartilage far removed from the
defect site. Thus, the histological scoring system shown in
Table II facilitated a thorough, systematic means of evaluat-
ing tissue quality and quantity in the overall 3  3 mm
defect, as well as in the subchondral (the bottom 2 mm) and
chondral (the upper 1 mm) regions of defects. Furthermore,
this comprehensive system allowed for assessment of pos-
sible degenerative changes in the tissue adjacent to defects.
Statistical analysis
Ordered logistic regression of histological scores was per-
formed using SAS Version 8.2 statistical software (SAS,
Cary, NC). This statistical method provides a means of
assessing potential factors affecting outcomes with discrete,
ordinal values.42 For each histological parameter, ordered
logistic regression was performed to analyze the potential
single factor affects of time, scaffold formulation, and loca-
tion within the defect (edge vs center sections). The Wald
chi-square test statistic with a signiﬁcance level of 0.05 was
ﬁrst used to conﬁrm the validity of each regression. An
analysis of effects was then performed with a signiﬁcance
level of 0.05. Potential two and three factor interactions
amongst time, scaffold formulation, and location were also
evaluated for each histological parameter.
Calculation of average histological scores
Ordered logistic regression revealed that section location
(edge vs center) within defects was not a signiﬁcant factor
affecting any of the 12 histological parameters. Thus, for
each parameter, the medial, lateral, and center scores for a
particular defect were averaged. Then, at each time point,
the mean score and corresponding standard deviation
amongst these averages was calculated for each treatment
TABLE II
Histological Scoring System for Evaluation of Overall
Tissue Filling (a), Subchondral Bone Repair (b), and
Cartilage Repair (c) in Rabbit, Osteochondral Defects
(a) Overall defect evaluation (throughout the entire defect depth) Score
1. Percent ﬁlling with neo-formed tissue
100% 3
50% 2
	50% 1
0% 0
2. Percent degradation of the implant
100% 3
50% 2
	50% 1
0% 0
(b) Subchondral bone evaluation (within the bottom 2 mm of
defect) Score
3. Percent ﬁlling with neo-formed tissue
100% 3
50% 2
	50% 1
0% 0
4. Subchondral bone morphology
Normal, trabecular bone 4
Trabecular, with some compact bone 3
Compact bone 2
Compact bone and ﬁbrous tissue 1
Only ﬁbrous tissue or no tissue 0
5. Extent of neo-tissue bonding with adjacent bone
Complete on both edges 3
Complete on one edges 2
Partial on both edges 1
Without continuity on either edge 0
(c) Cartilage evaluation (within the upper 1 mm of defect) Score
6. Morphology of neo-formed surface tissue
Exclusively articular cartilage 4
Mainly hyaline cartilage 3
Fibrocartilage 2
Only ﬁbrous tissue or bone 1
No tissue 0
7. Thickness of neo-formed cartilage
Greater than surrounding cartilage 3
Similar to the surrounding cartilage 2
Less than the surrounding cartilage 1
No cartilage 0
8. Joint surface regularity
Smooth, intact surface 3
Surface ﬁssures (	25% neo-surface thickness) 2
Deep ﬁssures (25–99% neo-surface thickness) 1
Complete dissruption of the neo-surface 0
9. Chondrocyte clustering
None at all 3
	25% chondrocytes 2
25–100% chondrocytes 1
No chondrocytes present (no cartilage) 0
10. Cell and glycoasminoglycan (GAG) content of neo-formed
cartilage
Normal cellularity with normal Safranin O staining 3
Normal cellularity with moderate Safranin O staining 2
Clearly less cells with poor Safranin O staining 1
Few cells with no or little Safranin O staining or no
cartilage 0
11. Collagen content
Normal 3
Moderately reduced 2
Severly reduced 1
Absent or no cartilage 0
12. Cell and glycoasminoglycan (GAG) content of adjacent
cartilage
Normal cellularity with normal GAG content 3
Normal cellularity with moderate GAG content 2
Clearly less cells with poor GAG content 1
Few cells with no or little GAGs or no cartilage 0
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group. These values are reported in Tables III and IV as
mean scores per formulation (MSF)  standard deviation.
It should be noted that for all parameters, except param-
eter 7, scores of maximum value correspond to the charac-
teristics of healthy, uninjured tissue. For parameter 7 (neo-
cartilage thickness), a score of 2, rather than the maximum
value of 3, corresponds to normal cartilage thickness. Al-
though neo-cartilage thickness was commonly observed to
be thinner than the surrounding cartilage, only one instance
of overﬁlling was noted. Thus, average scores for this pa-
rameter accurately represent relative tissue thickness.
RESULTS
Animal health and macroscopic joint appearance at
recovery
Animals appeared to recover quickly from the bi-
lateral surgical procedure and were observed to regain
full movement within less than 1 week. The rabbits
continued to exhibit no physical limitations, with nor-
mal behavior and movement observed throughout the
14-week period. It should be noted that complications
during the surgical creation of one defect led to exclu-
sion of that specimen from the study. With all other
defects, no signs of inﬂammation, infection, or swell-
ing were noticed upon visible inspection of the joint
surfaces at the time of tissue retrieval.
Histological appearance
Tissue repair at 4 weeks
No evidence of a persistent inﬂammatory response
was observed at 4 weeks despite the signiﬁcant extent
of implant degradation that was observed at this early
time point. Immature tissue was seen to ﬁll greater
than 50% of the defect area in histological sections of
joints treated with all scaffold formulations. The over-
all percentage of tissue ﬁlling and scaffold degrada-
tion appeared to vary among all defects, regardless of
scaffold type. Compact bone and a small amount of
ﬁbrous tissue generally ﬁlled the subchondral portion
of defects (the bottom 2 mm). However, in many
specimens, especially those with little scaffold mate-
rial remaining, some trabecular bone was already
present at this early time point. Overall, this osseous
tissue was well integrated with the surrounding bone.
Likewise, the newly formed tissue in the chondral
region of defects (the upper 1 mm) displayed continu-
ity with both the adjacent cartilage and underlying
subchondral tissue. This neo-surface had the appear-
ance of ﬁbrocartilage or ﬁbrous tissue and was gener-
ally thinner than the surrounding, uninjured cartilage.
Elongated, thin cells and sparse Safranin O staining
were observed at 4 weeks (Fig. 2). Some ﬁssures in the
neo-surface were present, but these generally did not
extend to the underlying bone. Both the subchondral
and chondral tissue adjacent to the defect site main-
tained a healthy appearance.
Tissue repair at 14 weeks
In general, by 14 weeks, defects were completely
ﬁlled with tissue, and scaffolds were completely de-
graded. With all treatment groups, the neo-formed
subchondral and chondral tissue had undergone con-
siderable remodeling between 4 and 14 weeks, as ap-
parent in the morphology of the newly formed tissue
at this later time point (Fig. 3). In some sections, the
only visible marker of the former defect area was a
slightly thinner cartilage layer with less intense Safra-
nin O staining than the surrounding joint surface.
Trabecular bone, and sometimes a small amount of
remaining compact bone, ﬁlled the subchondral re-
gion. In all cases, this bone was completely integrated
with the adjacent bone.
The new joint surface was also well-integrated with
the surrounding cartilage at 14 weeks, but was occa-
sionally dotted with ﬁssures as shown in Figure 3(i).
With all treatment groups, chondrocytes now popu-
lated the former defect area but were reduced in num-
ber when compared to the uninjured cartilage. These
chondrocytes were often arranged in a zonal organi-
zation resembling healthy articular cartilage. As
shown in the magniﬁcations of Figures 3(g) and 3(h),
chondrocytes near the joint surface were slightly elon-
gated. Below these cells, more rounded chondrocytes
were seen to form columns and to stain more intensely
for GAG, as expected for cells in the intermediate zone
of articular cartilage.3,43 Cartilage surrounding this
neo-formed surface maintained a healthy appearance
and thickness [Fig. 3(a–c)].
Histological scoring
Overall analysis
A general improvement among histological scores
for all treatment groups was observed between 4 and
14 weeks. In fact, statistical evaluation of scores re-
vealed that time was a signiﬁcant factor affecting tis-
sue and bone ﬁlling, bone and cartilage morphology,
cartilage thickness, and chondrocyte clustering, as
well as cell, GAG, and collagen content (parameters 1,
3–4, 6–7, and 9–12). Section location (edge vs center of
the defect) was not seen to be a signiﬁcant factor for
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any of the 12 histological scores at either time point.
Contrary to expectations, scaffold type (C /C, C /H,
or C/H) was only found to be a signiﬁcant factor
affecting one of the histological markers—in particu-
lar, joint surface regularity. Additional analysis re-
vealed that no two or three factor interactions were
present among time, location, and scaffold type.
Histological scores at 4 weeks
As previously discussed, some variability in tissue
ﬁlling and scaffold degradation was observed in 4
week sections. Again, scaffold type was not seen to
inﬂuence the degree of tissue ﬁlling or scaffold deg-
radation. Mean histological scores for subchondral
bone morphology were between 2.0 and 1.0 (Table III),
indicating the predominance of remodeling compact
bone with some remaining ﬁbrous tissue in this por-
tion of defects at 4 weeks. Contrary to expectations,
the material composition of the bottom layer of scaf-
folds did not inﬂuence bone ﬁlling, morphology, or
integration. However, no bone upgrowth into the
chondral region was observed with any of the treat-
ment groups.
Histological evaluation revealed that TGF-1 deliv-
ery had little effect on early cartilage repair. Regard-
less of treatment group, the neo-surface at 4 weeks
scored between 1.0 and 2.0 for surface tissue morphol-
ogy, reﬂecting the ﬁbrous nature of this new surface.
Critical histological scoring revealed that this tissue
was thinner and contained lower cell, GAG, and col-
lagen content than the surrounding uninjured carti-
lage (see Table III). Very limited degenerative changes
were observed in the cartilage adjacent to defects. As
shown in Table III, mean scores for cell and GAG
content in the surrounding cartilage tissue (parameter
12) were at or near 2.0 for all formulations, indicating
normal cellularity with moderately reduced GAG con-
tent. Again, these ﬁndings further conﬁrm the biocom-
patibility of these OPF composites and their degrada-
tion products. By 14 weeks, the surrounding cartilage,
as well as the neo-formed surface, displayed overall
improvements in tissue quality as reﬂected in the
higher histological scores at this later time point.
Histological scores at 14 weeks
In general, scaffolds were completely degraded at
14 week. Tissue ﬁlling was seen to statistically im-
prove by 14 weeks. However, perhaps the most strik-
ing improvements between 4 and 14 weeks were ob-
served in the morphology of both the subchondral and
chondral regions of the former defect areas. Although
the 4-week mean scores for subchondral bone mor-
Figure 2. Sections showing representative 4-week tissue repair in three defects after osteochondral implantation of C /C
(A and D), C /H (B and E), and C/H (C and F) scaffolds. (A–C) H&E-stained tissue sections; (D–F) sections stained with
Safranin O/light green. Original magniﬁcation of all sections is 2.5. Arrows point towards the joint surface, while surface
ﬁssures are respectively indicated by FI. [Color ﬁgure can be viewed in the online issue, which is available at www.
interscience.wiley.com.]
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phology were below 2.0 for all treatments, by 14 weeks
these scores had risen to 3.0  0.7, 2.7  0.6, 3.1  0.9,
for defects treated with C /C, C /H, and C/H,
respectively. Thus, the compact bone and ﬁbrous tis-
sue present at 4 weeks underwent signiﬁcant remod-
eling to form trabecular bone at 14 weeks. As shown in
Figure 3, this bone was completely integrated with the
surrounding bone. In fact, maximum scores of 3.0,
indicating complete bonding on both defect edges,
were awarded to all tissue sections evaluated at 14
weeks.
Tissue quality in the chondral portion of the former
defect area had also improved considerably by week
14 (see Fig. 3). In fact, scores for tissue morphology,
thickness, chondrocyte clustering, and cell, GAG, and
collagen content were statistically higher at 14 weeks
than at 4 weeks. For example, scores for cell and GAG
content, which had been at or below 1.0 at 4 weeks,
now approached 2.0 at 14 weeks, indicating an in-
crease in both cellularity and GAG content. Likewise,
scores for total collagen content were also seen to
improve between 4 and 14 weeks. Perhaps most in-
dicative of the overall improvement in tissue quality
were the elevated 14 week mean scores for surface
tissue morphology (2.9  0.6, 2.7  0.5, 2.6  0.8 for
C

/C, C /H, and C/H treatment groups, respec-
tively). These scores reﬂected the high frequency of
hyaline cartilage ﬁlling the chondral region and the
zonal arrangement of chondrocytes at 14 weeks. It
should be noted that this cartilage was still thinner
than the surrounding cartilage, but its thickness had
statistically improved between 4 and 14 weeks. Al-
Figure 3. Sections (stained with Safranin O/light green) showing representative 14-week tissue repair in three defects after
osteochondral implantation of C /C (A, D, and G), C /H (B, E, and H), and C/H (C, F, and I) scaffolds. The boxed regions
in (A–C) (2.5 magniﬁcation) are shown at higher magniﬁcations in (D–F) (10), and (G–I) (20). Arrows point towards the
joint surface, while columnar arrangements of chondrocytes, cell clusters, and cartilage ﬁssures are respectively indicated by
CO, CL, and FI. [Color ﬁgure can be viewed in the online issue, which is available at www.interscience.wiley.com.]
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though Safranin O staining in cartilage immediately
adjacent to the former defect was slightly reduced
(when compared to cartilage far from the defect site),
normal chondrocyte density and arrangement perpet-
uated this tissue, indicating that no severe, adverse
effects were inﬂicted by these OPF-based scaffolds.
DISCUSSION
The rigorous histological analysis undertaken in
this study allowed for critical evaluation of tissue
repair in osteochondral defects treated with three dif-
ferent formulations of OPF hydrogel scaffolds. More
speciﬁcally, the 12-parameter system shown in Table
II permitted individual assessment of the neo-formed
tissue in both the subchondral and chondral regions of
defects. At either time point and in either region of the
defect, no evidence of persistent inﬂammation was
observed. Overall, at 4 weeks, scaffolds were largely
degraded with immature tissue-ﬁlling defects. Al-
though mainly compact bone with some ﬁbrous tissue
ﬁlled the subchondral region at 4 weeks, this tissue
had been remodeled to contain predominantly trabec-
ular bone at 14 weeks. Likewise, the ﬁbrocartilage
ﬁlling the subchondral region of defects at 4 weeks
had been remodeled to contain mainly hyaline carti-
lage at 14 weeks.
This observed improvement in bone and cartilage
morphology indicate the biocompatibility of these
OPF-based scaffolds and their degradation products.
In previous in vitro studies, designed to model the low
pH environment typical of prolonged inﬂammation,
OPF-gelatin microparticle composites and OPF hydro-
gels were seen to degrade at a relatively slow rate at
decreased pH. In fact, less than 60% polymer loss was
observed at pH 4.0 after 4 weeks.14 In the present
study, scaffold degradation in vivo generally exceeded
60% at 4 weeks. Thus, this observation indicates that
low pH, and thus an inﬂammatory environment, did
not persist around the defect site. Furthermore, be-
cause neither inﬂammatory cells nor joint swelling
were observed at either 4 or 14 weeks, the biocompat-
ibility of the byproducts from these degrading OPF
scaffolds is clearly conﬁrmed.
In this study, the observed rate of implant degrada-
tion conformed to the expected degradation kinetics
for scaffold layers consisting of an OPF–gelatin micro-
particle composite at normal, physiological condi-
tions.14 However, layers containing OPF gels with no
microparticles were expected to degrade at a slower
rate, as complete degradation at pH 7.4 within 4 weeks
was not observed in prior in vitro studies.14 Compres-
sive loading during normal, joint movement may ex-
plain this enhanced rate of gel degradation. Scaffold
type, and thus composition, did not appear to greatly
affect the extent of repair. However, bone upgrowth
into the chondral region was not observed with either
material composition, demonstrating that both com-
positions have degradation rates that support con-
trolled osteochondral repair. The similar in vivo deg-
radation proﬁles of these scaffolds may account for the
similar healing responses observed among scaffold
formulations.
Like scaffold degradation, bone integration was not
observed to signiﬁcantly change between 4 and 14
weeks. Although partial integration was occasionally
observed at the early time point, 4 week scores for this
parameter were not found to be statistically different
from the complete integration observed at 14 weeks.
TABLE III
Mean Histological Scores per Scaffold Formulation (MSF) at 4 Weeks Postsurgery
Histological Parameter
Mean Score per Formulation
C/C (n 
 4) C/H (n 
 6) C/H (n 
 5)
Overall defect evaluation
1. Percent ﬁlling with neo-formed tissue 2.2 0.8 2.7 0.4 2.3 0.7
2. Percent degradation of the implant 2.7 0.5 2.7 0.4 2.3  0.7
Subchondral bone evaluation
3. Percent ﬁlling with neo-formed tissue 2.0 0.7 2.1  1.1 2.1 0.8
4. Subchondral bone morphology 1.5 1.1 1.5  1.0 1.7 0.7
5. Extent of neo-tissue bonding with adjacent bone 2.0 1.0 2.1  1.3 3.0 0.0
Cartilage evaluation
6. Morphology of neo-formed surface tissue 1.8 0.6 1.6 0.5 1.6 0.5
7. Thickness of neo-formed cartilage 1.3 1.0 0.7 0.4 0.8 0.8
8. Joint surface regularity 2.6 0.5 2.0 0.6 1.7 0.8
9. Chondrocyte clustering 1.6 1.1 1.2 1.0 0.9 0.9
10. Cell and GAG content of neo-formed cartilage 1.1 0.8 0.7 0.8 0.8  0.8
11. Collagen content 1.7 1.2 1.2  0.9 1.3 1.3
12. Cell and GAG content of adjacent cartilage 2.3 0.3 1.8  0.3 2.6 0.4
Values are shown as mean  standard deviation.
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Often, when grafts7 or degradable scaffolds35,36 are
utilized in cartilage repair, incomplete integration
with the surrounding tissue is observed upon long-
term evaluation. This may lead to displacement of the
implant and inﬂict further joint pain.7 Thus, the excel-
lent tissue integration exhibited with these novel scaf-
folds demonstrates their potential in advancing the
treatment of cartilage lesions.
Likewise, the lack of statistical changes in joint sur-
face regularity scores reﬂects the utility of these scaf-
folds in cartilage engineering. At both 4 and 14 weeks,
disruptions in the joint surface were generally limited
to surface ﬁssures, as indicated by the histological
scores in Tables III and IV. It should be noted that
scaffold type was seen to affect this marker of cartilage
repair. In particular, higher scores corresponded with
TGF-1-loaded scaffolds. Although these results sug-
gest some therapeutic effect of the TGF-1 released
from these scaffolds, further research is necessary to
investigate why growth factor delivery did not affect
additional markers of tissue repair. Because other re-
searchers have also encountered a lack of signiﬁcant
differences between treatment groups upon histolog-
ical evaluation of osteochondral scaffolds,36,44 this is-
sue may be related to the complexity of articular car-
tilage repair and/or the use of relatively young
animals with higher regenerative potential. Although
numerous other studies have also utilized the current
animal model,35,36 future studies will investigate these
scaffolds for osteochondral repair in older animals.
However, the excellent tissue ﬁlling and integration
resulting from osteochondral implantation of these
novel OPF-based scaffolds demonstrates their poten-
tial for improving cartilage repair. As shown in Figure
3, hyaline cartilage with well-organized chondrocytes
and intense GAG staining was seen to ﬁll the chondral
portion of defects at 14 weeks. Trabecular bone with
some remodeling compact bone was seen to ﬁll the
subchondral region. Untreated rabbit osteochondral
defects have been shown to be ﬁlled with highly ﬁbril-
lar, ﬁbrous tissue or ﬁbrocartilage in the chondral
region with bone up to or beyond the tidemark.35
Accordingly, the quality of repair achieved with these
scaffolds reveals their promise in advancing cartilage
repair and compels further in vivo investigations with
these materials.
CONCLUSIONS
Through osteochondral implantation of OPF-based
hydrogels, the potential of this novel class of degrad-
able scaffolds has been demonstrated in the ﬁeld of
cartilage tissue engineering. Speciﬁcally, this research
illustrates that OPF-based hydrogel scaffolds undergo
biocompatible degradation and support healthy tissue
growth in rabbit osteochondral defects. Tissue quality
was seen to improve over time with mostly hyaline
cartilage ﬁlling the chondral region and a mixture of
trabecular and compact bone ﬁlling the subchondral
region at 14 weeks. Although scaffold material com-
position was not seen to affect scaffold degradation or
tissue ﬁlling, no bone upgrowth into the chondral
region was observed, and new bone tissue was com-
pletely integrated with the surrounding bone at 14
weeks. Although further studies are necessary to op-
timize these scaffolds, TGF-1 loading in the top layer
of scaffolds appeared to exert some affect on cartilage
quality in the defect area. Accordingly, this research
TABLE IV
Mean Histological Scores per Scaffold Formulation (MSF) at 14 Weeks Postsurgery
Histological Parameter
Mean Score per Formulation
C/C (n 
 4) C/H (n 
 6) C/H (n 
 5)
Overall defect evaluation
1. Percent ﬁlling with neo-formed tissue* 2.8 0.3 2.6 0.2 2.9 0.2
2. Percent degradation of the implant 2.8 0.3 2.6 0.2 2.9  0.2
Subchondral bone evaluation
3. Percent ﬁlling with neo-formed tissue* 2.8 0.3 2.7  0.3 2.9 0.2
4. Subchondral bone morphology* 3.0 0.7 2.7  0.6 3.1 0.9
5. Extent of neo-tissue bonding with adjacent bone 3.0 0.0 3.0  0.0 3.0 0.0
Cartilage evaluation
6. Morphology of neo-formed surface tissue* 2.9 0.6 2.7 0.5 2.6 0.8
7. Thickness of neo-formed cartilage* 1.7 0.4 1.7 0.2 1.5 0.6
8. Joint surface regularity 2.6 0.5 2.4 0.4 2.2 0.3
9. Chondrocyte clustering* 2.1 0.7 1.7 0.4 1.9 0.7
10. Cell and GAG content of neo-formed cartilage* 1.9 0.6 1.7 0.5 1.7  0.6
11. Collagen content* 2.3 0.7 2.2  0.6 2.4 1.0
12. Cell and GAG content of adjacent cartilage* 2.8 0.3 2.7  0.3 2.6 0.4
Values are shown as mean  standard deviation. Asterisks (*) indicate those parameters which were shown to statistically
improve over time from 4-week values.
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demonstrates the exciting potential of these OPF-
based hydrogels as carriers of bioactive agents for
cartilage repair.
The authors acknowledge the expert guidance of Drs.
Arnold Caplan and Jizong Gao of Case Western Reserve
University with the animal model, and Dr. Pieter Buma, of
the University Medical Center Nijmegen with the scoring
system.
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